Items where authors include "Price, E."

Article

Abani, O., Abbas, A., Abbas, F. et al. (8021 more authors) (2025) Higher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. eClinicalMedicine, 81. 103080. ISSN 2589-5370

Mills, T.J., Price, E., Aggarwal, V.R. orcid.org/0000-0003-0838-9682 et al. (2 more authors) (2024) Oral health and dental care challenges in scleroderma - perspectives of dentists, rheumatologists, and patients. Rheumatology Advances in Practice, 8 (4). rkae121. ISSN 2514-1775

Mills, T.J., Price, E., Aggarwal, V.R. orcid.org/0000-0003-0838-9682 et al. (2 more authors) (2024) Clinician and Patient Experiences of Managing and Living with Oral and Dental Manifestations of Scleroderma: A Scoping Review. Journal of Scleroderma and Related Disorders, 9 (2). 86 -98. ISSN 2397-1983

Faust, S.N., Haynes, R., Jones, C.E. et al. (7370 more authors) (2024) Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Child & Adolescent Health, 8 (3). pp. 190-200. ISSN 2352-4642

Abhishek, A., Peckham, N., Pade, C. et al. (65 more authors) (2024) Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial. The Lancet Rheumatology, 6 (2). e92-e104. ISSN 2665-9913

Abani, O., Abbas, A., Abbas, F. et al. (7989 more authors) (2023) Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet Diabetes & Endocrinology, 11 (12). pp. 905-914. ISSN 2213-8587

Abani, O., Abbas, A., Abbas, F. et al. (8104 more authors) (2023) Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet, 401 (10387). pp. 1499-1507. ISSN 0140-6736

Ng, W.F., Miller, A., Bowman, S.J. et al. (96 more authors) (2016) Physical activity but not sedentary activity is reduced in primary Sjögren’s syndrome. Rheumatology International. ISSN 0172-8172

Howard Tripp, N., Tarn, J., Natasari, A. et al. (29 more authors) (2016) Fatigue in primary Sjögren's syndrome is associated with lower levels of proinflammatory cytokines. RMD Open, 2 (2). e000282. ISSN 2056-5933